| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7553840 | TERSERA | 4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds and methods of their use |
Dec, 2027
(3 years from now) | |
| US8193204 | TERSERA | Solid forms of (S)-ethyl 2-amino-3-(4-(2-amino-6-((R)-1- (4-chloro-2-(3-methyl-1H-pyrazol-1-YL)phenyl)2,2,2-trifluoroethoxy)-pyrimidin-4-YL)phenyl)propanoate and methods of their use |
Feb, 2031
(6 years from now) | |
| US7709493 | TERSERA | 4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds and methods of their use |
Feb, 2031
(6 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7968559 | TERSERA | Methods of using 4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds |
Dec, 2027
(3 years from now) | |
| US8653094 | TERSERA | Solid forms of (S)-ethyl 2-amino-3-(4-(2-amino-6-((R)-1-(4-chloro-2-(3-methyl-1H-pyrazol-1-yl)phenyl)-2,2,2-trifluoroethoxy)-pyrimidin-4-yl)phenyl)propanoate and methods of their use |
Dec, 2028
(4 years from now) | |
Xermelo is owned by Tersera.
Xermelo contains Telotristat Etiprate.
Xermelo has a total of 5 drug patents out of which 0 drug patents have expired.
Xermelo was authorised for market use on 28 February, 2017.
Xermelo is available in tablet;oral dosage forms.
Xermelo can be used as the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog (ssa) therapy in adults inadequately controlled by ssa therapy.
Drug patent challenges can be filed against Xermelo from 28 February, 2021.
The generics of Xermelo are possible to be released after 28 February, 2031.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-132) | Feb 28, 2024 |
| Orphan Drug Exclusivity(ODE) | Feb 28, 2024 |
| New Chemical Entity Exclusivity(NCE) | Feb 28, 2022 |
Drugs and Companies using TELOTRISTAT ETIPRATE ingredient
NCE-1 date: 28 February, 2021
Market Authorisation Date: 28 February, 2017
Treatment: The treatment of carcinoid syndrome diarrhea in combination with somatostatin analog (ssa) therapy in adults inadequately controlled by ssa therapy
Dosage: TABLET;ORAL
XERMELO family patents
